ArticlemAbs2019
Selection and characterization of FcεRI phospho-ITAM specific antibodies.
Article in mAbs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- In Vitro Selection of Antibodies TargetingPathogens (Basel, Switzerland) · 2026Article
- Discovering Novel Therapeutic VbioRxiv : the preprint server for biology · 2026Article
- Discovering novel therapeutic VFrontiers in immunology · 2026Article
- Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential.PloS one · 2024Article
- Yeast biopanning against site-specific phosphorylations in tau.Protein engineering, design & selection : PEDS · 2023Article
- Direct selection of functional fluorescent-protein antibody fusions by yeast display.PloS one · 2023Article
- Healthy humans can be a source of antibodies countering COVID-19.Bioengineered · 2022Article
- Construction, characterization and crystal structure of a fluorescent single-chain Fv chimera.Protein engineering, design & selection : PEDS · 2021Article
- Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy.International journal of peptide research and therapeutics · 2021Review
- Development of Anti-ImmunoTargets and therapy · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Post-translational modifications, such as the phosphorylation of tyrosines, are often the initiation step for intracellular signaling cascades. Pan-reactive antibodies against modified amino acids (e.g., anti-phosphotyrosine), which are often used to assay these changes, require isolation of the specific protein prior to analysis and do not identify the specific residue that has been modified (in the case that multiple amino acids have been modified). Phosphorylation state-specific antibodies (PSSAs) developed to recognize post-translational modifications within a specific amino acid sequence can be used to study the timeline of modifications during a signal cascade. We used the FcεRI receptor as a model system to develop and characterize high-affinity PSSAs using phage and yeast display technologies. We selected three β-subunit antibodies that recognized: 1) phosphorylation of tyrosines Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.